Literature DB >> 27302851

Augmented Renal Clearance in Traumatic Brain Injury: A Single-Center Observational Study of Atrial Natriuretic Peptide, Cardiac Output, and Creatinine Clearance.

Andrew A Udy1,2, Paul Jarrett3, Melissa Lassig-Smith3, Janine Stuart3, Therese Starr3, Rachel Dunlop3, Renae Deans3, Jason A Roberts3,4,5, Siva Senthuran6, Robert Boots3, Kavita Bisht7, Andrew C Bulmer7, Jeffrey Lipman3,5.   

Abstract

Augmented renal clearance (ARC) is being increasingly described in neurocritical care practice. The mechanisms driving this phenomenon are largely unknown. The aim of this project was therefore to explore changes in renal function, cardiac output (CO), and atrial natriuretic peptide (ANP) concentrations in patients with isolated traumatic brain injury (TBI). This prospective observational cohort study was conducted in a tertiary-level, university-affiliated intensive care unit (ICU). Patients with normal plasma creatinine concentrations (<120 μmol/L) at admission and no history of chronic kidney disease, admitted with isolated TBI, were eligible for enrollment. Continuous CO measures were obtained using arterial pulse waveform analysis. Eight-hour urinary creatinine clearances (CLCR) were used to quantify renal function. ANP concentrations in plasma were measured on alternate days. Data were collected from study enrollment until ICU discharge, death, or day 15, which ever came first. Eleven patients, contributing 100 ICU days of physiological data, were enrolled into the study. Most participants were young men, requiring mechanical ventilation. Median ICU length of stay was 9.6 [7.8-13.0] days. Elevated CLCR measures (>150 mL/min) were frequent and appeared to parallel changes in CO. Plasma ANP concentrations were also significantly elevated over the study period (minimum value = 243 pg/mL). These data suggest that ARC is likely to complicate the care of TBI patients with normal plasma creatinine concentrations, and may be driven by associated cardiovascular changes and/or elevated plasma ANP concentrations. However, significant additional research is required to further understand these findings.

Entities:  

Keywords:  biomarkers; clinical management of CNS injury; traumatic brain injury

Mesh:

Substances:

Year:  2016        PMID: 27302851     DOI: 10.1089/neu.2015.4328

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  19 in total

1.  A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges.

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Wai Tat Wong; Gavin M Joynt; Menino Osbert Cotta
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

2.  The Impact of Capping Creatinine Clearance on Achieving Therapeutic Vancomycin Concentrations in Neurocritically Ill Patients with Traumatic Brain Injury.

Authors:  Nicholas R Nelson; Kathryn A Morbitzer; J Dedrick Jordan; Denise H Rhoney
Journal:  Neurocrit Care       Date:  2019-02       Impact factor: 3.210

3.  Augmented Renal Clearance in Critically Ill Patients: A Systematic Review.

Authors:  Idoia Bilbao-Meseguer; Alicia Rodríguez-Gascón; Helena Barrasa; Arantxazu Isla; María Ángeles Solinís
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 4.  Acute Kidney Injury at the Neurocritical Care Unit.

Authors:  Gonzalo Ramírez-Guerrero; Romyna Baghetti-Hernández; Claudio Ronco
Journal:  Neurocrit Care       Date:  2021-09-13       Impact factor: 3.210

5.  Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study.

Authors:  Nilesh Kumta; Aaron J Heffernan; Menino Osbert Cotta; Steven C Wallis; Amelia Livermore; Therese Starr; Wai Tat Wong; Gavin M Joynt; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2022-07-06       Impact factor: 5.938

6.  Evaluation of Levetiracetam Dosing Strategies for Seizure Prophylaxis Following Traumatic Brain Injury.

Authors:  Kelsey Ohman; Bridgette Kram; Jennifer Schultheis; Jana Sigmon; Safa Kaleem; Zidanyue Yang; Hui-Jie Lee; Cory Vatsaas; Jordan Komisarow
Journal:  Neurocrit Care       Date:  2022-09-27       Impact factor: 3.532

Review 7.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

8.  Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study.

Authors:  Idoia Bilbao-Meseguer; Helena Barrasa; Alicia Rodríguez-Gascón; Eduardo Asín-Prieto; Javier Maynar; José Ángel Sánchez-Izquierdo; María Ángeles Solinís; Arantxazu Isla
Journal:  J Intensive Care       Date:  2022-04-21

9.  Plasma metabolomics profiles in rats with acute traumatic brain injury.

Authors:  Fei Zheng; Zi-An Xia; Yi-Fu Zeng; Jie-Kun Luo; Peng Sun; Han-Jin Cui; Yang Wang; Tao Tang; Yan-Tao Zhou
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

10.  Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?

Authors:  Helena Colom-Codina; Ariadna Padullés-Zamora; Erika Esteve-Pitarch; Víctor Daniel Gumucio-Sanguino; Sara Cobo-Sacristán; Evelyn Shaw; Kristel Maisterra-Santos; Joan Sabater-Riera; Xosé L Pérez-Fernandez; Raül Rigo-Bonnin; Fe Tubau-Quintano; Jordi Carratalà
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-06-15       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.